Julie VERAN obtained her doctorate in Immunology in 2004 at Aix Marseille University (AMU) (within the Paoli-Calmettes Institute, Center for Research and the Fight against Cancer). During her doctorate, she participated in the establishment of a pioneering clinical trial aimed at evaluating vaccination by dendritic cells in breast cancer in partnership with a Swiss pharmaceutical manufacturer. She also holds a university degree in cell and gene therapy obtained from the University of Montpellier in 2007.
In 2007, she became production manager at the opening of the Cellular Therapy department of lAssistance Publique Hôpitaux de Marseille (AP-HM) and, since then, has coordinated in particular the regulatory procedures associated with the implementation of clinical trials and routine care cell therapy preparations with the National Agency for the Safety of Medicines and Health products (ANSM). In 2013, she obtained a Specialized Master's degree in Quality, Safety and Environment and has since held the position of Quality Assurance Manager.
Since 2012, she has been a “Responsible Person (PRI)” within the framework of the activities of innovative therapy medicinal products – prepared on an ad hoc basis (MTI-PP) within the AP-HM: the cell therapy department is implementing several clinical trials early phase in various indications aimed at evaluating the safety and effectiveness of innovative products including autologous Stromal Vascular Fraction derived from adipose tissue or those of “composite” products combining platelet-rich plasma and products derived from adipose tissue. She currently coordinates the operational and regulatory aspects of the manufacturing of experimental MTI-PP batches for therapeutic use, interfacing with medical teams. She actively participates in the development of innovative MTIs (such as those manufactured by 3D bioprinting) and formalizes the elements relating to their transfer from research to the clinic.
Very frequently, she sits as an expert on numerous independent monitoring committees of early phase clinical trials of biotherapies. She currently specializes in the technical and regulatory aspects of cryopreservation and biobanking.
Apart from her clinical activity, Julie VERAN is involved in university teaching in Aix-Marseille University and member of the board of the learned society “The French Society of Cellular and Tissue Bioengineering”. She is co-author of more than 40 international scientific publications and speaks at conferences dedicated to biotherapies and therapeutic innovations.
